Journal of Hematology & Oncology

official impact factor 2.93

Open Access

New dosing schedules of dasatinib for CML and adverse event management

Siu-Fun Wong

Journal of Hematology & Oncology 2009, 2:10 doi:10.1186/1756-8722-2-10

Accesses  

  • Last 30 days: 113 accesses
  • Last 365 days: 1778 accesses
  • All time: 5533 accesses